RICHMOND, Va., April 22 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOBs) and biopharmaceuticals, announced today that Geoffrey Allan, Ph.D., CEO of Insmed, will present at the Center for Business Intelligence (CBI) conference on FOBs, on April 29, 2008 at 2:15 PM Eastern Time in Arlington, Virginia.
The conference, entitled "Evaluate the Legislative, Economic and Scientific Implications of the Industry Debate on: Biosimilars and Follow-On Biologics," will be held at the Doubletree Hotel Crystal City in Arlington, Virginia, and will run from Monday, April 28 through Tuesday, April 29. The conference will bring together corporate, regulatory, financial, and legal experts in the field of FOBs. Dr. Allan will discuss Insmed's comprehensive portfolio of FOBs, and the Company's initiatives aimed at helping garner awareness of the need to establish a regulatory pathway for FOBs in the U.S. so that patients can be provided greater choice through access to these important medicines. His presentation will be entitled, "The Promise of Follow-On Biologics: The Need to Match Policy with Capability and Demand." Dr. Allan's presentation will be available on Insmed's website at http://www.insmed.com following the conference.
The Follow-on Biologics Market
According to published reports, an estimated $10 billion worth of
biologic drugs are expected to come off patent by 2010, with an additional
$10 billion by 2015. FOBs would provide safe and effective therapies at a
reduced cost following the expiration of the original product's patent. A
recent econometric study commissioned by Insmed and conducted by economist
Dr. Robert J. Shapiro, former Under Secretary of Commerce in the Clinton
Administration, found that "...generic versions of the top 12 categories of
biologic treatments with patent protections that have expired or that are
due to expire in the near fu
|SOURCE Insmed Inc.|
Copyright©2008 PR Newswire.
All rights reserved